Results 11 to 20 of about 401,950 (315)
Cancer Discovery, 2012 Abstract Erlotinib and gefitinib inhibit the growth of non–small cell lung cancer tumors that harbor activating epidermal growth factor receptor (EGFR) mutations but are ineffective against EGFR variants found in glioblastoma. New studies by Barkovich and colleagues and Vivanco and colleagues show that these drugs only occupy the active ...
Jin H, Park, Mark A, Lemmon
openaire +2 more sources
Clinical Journal of the American Society of Nephrology, 2009 GFR is the accepted metric for evaluating renal function but measuring it directly (mGFR) can be cumbersome, time-consuming, and costly. The constant infusion method using inulin as the filtration marker, introduced in 1934 by Richards and Smith (1), has undergone many revisions that have now made mGFR easier to perform, although not widely available ...
Richard J. Glassock +1 more
openaire +1 more source
Optimized EGFR Blockade Strategies in EGFR Addicted Gastroesophageal Adenocarcinomas [PDF]
Clinical Cancer Research, 2021 Abstract Purpose: Gastric and gastroesophageal adenocarcinomas represent the third leading cause of cancer mortality worldwide. Despite significant therapeutic improvement, the outcome of patients with advanced gastroesophageal adenocarcinoma is poor. Randomized clinical trials failed to show a
Simona Corso +41 more
openaire +4 more sources
EGFR‐AS1 Promotes Bladder Cancer Progression by Upregulating EGFR [PDF]
BioMed Research International, 2020 Long noncoding RNAs play an essential role in bladder cancer progression. The role of long noncoding RNA EGFR‐AS1 in bladder cancer needs further study. We used clinical specimens to analyze the relationship between EGFR‐AS1 and bladder cancer patients’ characteristics.
Anbang Wang +8 more
openaire +2 more sources
Brk/PTK6 sustains activated EGFR signaling through inhibiting EGFR degradation and transactivating EGFR [PDF]
Oncogene, 2012 Epidermal growth factor receptor (EGFR)-mediated cell signaling is critical for mammary epithelial cell growth and survival; however, targeting EGFR has shown no or only minimal therapeutic benefit in patients with breast cancer. Here, we report a novel regulatory mechanism of EGFR signaling that may explain the low response rates. We found that breast
Li, X +7 more
openaire +2 more sources
EGFR-TKIs resistance via EGFR-independent signaling pathways [PDF]
Molecular Cancer, 2018 Tyrosine kinase inhibitors (TKIs)-treatments bring significant benefit for patients harboring epidermal growth factor receptor (EGFR) mutations, especially for those with lung cancer. Unfortunately, the majority of these patients ultimately develop to the acquired resistance after a period of treatment.
Qian Liu +5 more
openaire +3 more sources
Cell, 2012 The epidermal growth factor receptor (EGFR) is normally activated by ligand-induced dimerization. Oncogenic mutations in EGFR promote activation in a largely ligand-independent manner. Shan et al. uncover a partially disordered state of EGFR kinase, providing evidence that oncogenic mutations counteract this intrinsic structural instability to promote ...
Eck, Michael J., Hahn, William C.
openaire +2 more sources
Archives of Medical Science, 2019 Introduction Gefitinib, well known as a new antitumor agent, has been applied in various cancers such as oral squamous cell carcinoma (OSCC). However, most patients eventually acquire resistance to gefitinib, and the molecular mechanism of gefitinib ...
Huang Jin +3 more
doaj +1 more source
NF-κB signaling and crosstalk during carcinogenesis
4 open, 2019 Transcription factors (TFs) are proteins that control the transcription of genetic information from DNA to mRNA by binding to specific DNA sequences either on their own or with other proteins as a complex.
Brücher Björn L.D.M. +2 more
doaj +1 more source
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M [PDF]
Nature, 2009 The clinical efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation. Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are associated with toxicity ...
Zhou, Wenjun +14 more
openaire +3 more sources